Compare FDX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDX | REGN |
|---|---|---|
| Founded | 1971 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7B | 79.4B |
| IPO Year | 1997 | 1995 |
| Metric | FDX | REGN |
|---|---|---|
| Price | $354.08 | $749.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 24 |
| Target Price | $341.52 | ★ $819.54 |
| AVG Volume (30 Days) | ★ 1.4M | 505.8K |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | ★ 1.64% | 0.50% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 7.50 | ★ 41.48 |
| Revenue | ★ $65,450,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $6.53 | $11.69 |
| Revenue Next Year | $4.17 | $10.06 |
| P/E Ratio | $47.26 | ★ $18.32 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $194.30 | $476.49 |
| 52 Week High | $392.86 | $821.11 |
| Indicator | FDX | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 44.34 |
| Support Level | $347.91 | $740.39 |
| Resistance Level | $392.86 | $788.69 |
| Average True Range (ATR) | 8.30 | 20.59 |
| MACD | -4.72 | -3.18 |
| Stochastic Oscillator | 13.71 | 26.74 |
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In fiscal 2025, the firm's Federal Express segment—which houses the core package delivery operations—made up 86% of total revenue, with 10% coming from FedEx Freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).